Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of bumetanide in children and adolescents with autism spectrum disorders
2013-003259-39Phase 2Completed
- Sponsor
- Neurochlore
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bumetanide in Autism Spectrum Disorder (ASD), sponsored by Neurochlore. Primary endpoint: Change in CARS from baseline to Day 90. Started Feb 2014; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2013-003259-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003259-39.